Clinical study follows men with specific genetic changes to determine their risk for developing prostate cancer 

Prostate cancer (PC) is the most common malignancy in American men. There is increasing evidence that there may be a link between PC and men who have a family history of ovarian or breast cancer. As researchers have learned more about the role of genetics in PC, they have taken a new approach to screening for the disease—targeting men whose genetic profiles put them at risk for developing PC. Read more...

NCI connect

View the new NCI-CONNECT video on YouTube

Dec 27, 2018

NCI-CONNECT (Comprehensive Oncology Network Evaluating Rare CNS Tumors) aims to advance the understanding of rare adult central nervous system (CNS) cancers by establishing and fostering patient-advocacy-provider partnerships and networks to improve approaches to care and treatment. Learn more about NCI-CONNECT through this new video. Read more...

View the new NCI-CONNECT video on YouTube
Stephen Katz

In Memoriam: Stephen Katz, M.D., Ph.D.

Dec 21, 2018

Stephen Katz, M.D., Ph.D., Director of the National Institute of Arthritis and Musculoskeletal and Skin Diseases and former Senior Investigator in the Dermatology Branch at the Center for Cancer Research, died suddenly on December 20, 2018, at the age of 77. Dr. Katz served as a senior investigator in the Dermatology Branch from 1974-2014 and became acting chief in 1977. In 1980, he became chief of the branch, a position he held until 2002. “Steve had extraordinary abilities in research, administration and training,” said NCI Deputy Director Doug Lowy, M.D. “For example, he made the Dermatology Branch the place to come for training in dermatology research and was responsible for training many American and foreign leaders in the field.” Read more...

In Memoriam: Stephen Katz, M.D., Ph.D.
Steve Rosenberg

Steve Rosenberg featured in National Geographic article on personalized medicine

Dec 20, 2018

Steve Rosenberg, M.D., Ph.D., Chief of the Surgery Branch, was recently featured in a National Geographic article on how personalized medicine is transforming health care. The article highlights Judy Perkins, a metastatic breast cancer patient who was successfully treated with an experimental immunotherapy by Dr. Rosenberg.   Read more...

Steve Rosenberg featured in National Geographic article on personalized medicine
Ken Kraemer

Ken Kraemer discusses xeroderman pigmentosum with various media outlets

Dec 19, 2018

Kenneth Kraemer, M.D., Senior Investigator in the Laboratory of Cancer Biology and Genetics, has been featured by several media outlets discussing xeroderma pigmentosum (XP), a very rare skin disorder that makes a person highly sensitive to sunlight and prone to developing skin cancers. Dr. Kraemer provided some background on the dangers of living with XP for a Russia Today documentary and discussed the use of three large databases to estimate the prevalence of defective DNA repair variants in the United States with MedicalResearch.com. Read more...

Ken Kraemer discusses xeroderman pigmentosum with various media outlets
Horizons cover

New CCR publication, Horizons, is now available

Dec 18, 2018

As Nobel-Prize-winning physicist Niels Bohr once said, “Prediction is very difficult, especially about the future.” Yet, several areas of research that promise new understanding and treatments of cancer are coming into view. In this magazine, we highlight several areas of investigation likely to shape future research conducted in CCR. The collection in Horizons is by no means complete but seeks to capture some of the major areas that will influence our future work. Read more...

New CCR publication, Horizons, is now available
KRAS structure

Clinical trials evaluate T-cell transfer therapy for cancers with a mutated KRAS gene

Dec 17, 2018

KRAS mutations are present in up to a quarter of all human cancers, and eligible patients in a new clinical trial will undergo gene transfer therapy that uses their own blood cells. Investigators want to see if anti-KRAS T cells can make tumors shrink and whether this therapy has tolerable side effects.  Read more...

TFF1 gene

Sophisticated technology reveals gene expression in real time

Dec 13, 2018

CCR researchers made use of CRISPR-Cas9 and other technology to reveal gene expression in real time, demonstrating that RNA synthesis is highly variable due to long intervals between RNA production. The research supports the emerging awareness about the dynamic nature of gene expression and the tremendous variability among genes. Read more...

CellMiner

Researchers create record-sized, integrated cellular cancer database

Dec 12, 2018

Investigators in CCR have consolidated and expanded some of the world’s largest cancer databases to create an integrated, comprehensive cellular databank. The publicly available tool, called CellMinerCDB, can be used to explore in unprecedented detail the relationship between drugs, mutations, copy number, methylation and gene and protein expression. Read more...

logo

Registration is now open for the 2019 RNA Biology Symposium

Dec 10, 2018

RNA biology has emerged as one of the most influential areas in modern biology and biomedicine. The discovery of numerous new classes of RNAs and their function in a wide spectrum of biological processes has revolutionized molecular biology and has profound implications for clinical sciences. Key areas of current research include the elucidation of RNA biogenesis and structure, the identification of functions for various classes of RNAs, establishing the role of RNA in disease and the exploration of RNA-based and RNA-targeted therapies. Organized by the CCR Initiative in RNA Biologythis symposium will bring together internationally renowned experts in the field of RNA biology. Read more...

Registration is now open for the 2019 RNA Biology Symposium
RAS-driven cancer

Protein mutations lead to human disease by altering a cancer-promoting pathway

Dec 7, 2018

Working in collaboration with a team of other scientists, CCR researchers identified the role that the LZTR1 protein plays in disrupting the RAS pathway. It interferes with signaling, largely by dysregulating ubiquitination, a process defined as the attachment of a small protein called ubiquitin to a protein that is degraded by an enzyme. Read more...

Pages